Citations 1
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma
Adenocarcinoma, Expert Panel Adjuvant Therapy for Treatment of Locoregional Gastric, Tchelebi, Leila T. , Jin, Zhaohui, Attallah, Joseph, Abood, G., Akselrod, Dmitriy, Codipilly, D. Chamil, Dozois, Eric J. , Hallemeier, Christopher L., Krishan, Jethwa, Kennedy, Timothy, Lee, Percy P., Ling, Diane, Newman, Neil B. , Sharma, Navesh K, Small, William, Russo, Suzanne , Tchelebi, Leila , Jin, Zhaohui , Abood, Gerard, Akselrod, Dmitriy , Anker, Christopher J. , Codipilly, Don C. , Hallemeier, Christopher Leigh , Lee, Percy , Miller, Eric D. , Sharma, Navesh, Small, William , Russo, Suzanne
American Journal of Clinical Oncology | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Objectives: To summarize recent high-quality trials and provide an update to the original 2022 American College of Radiology Appropriate Use Criteria for Treatment of Locoregional Gastric Adenocarcinoma. This multi-specialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Methods: Using the population, intervention, comparator, outcome, timing, and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II/II trials and select retrospective studies published between 5/1/2020 and 8/1/2025 in the Embase, Medline, and Pubmed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include adjuvant FLOT chemotherapy for localized gastric adenocarcinoma after neoadjuvant FLOT and surgery, poCT or perioperative chemoimmunotherapy for localized gastric adenocarcinoma, adjuvant chemotherapy +/− CRT for localized gastric adenocarcinoma that undergoes upfront surgery, and systemic therapy alone for localized gastric adenocarcinoma in a medically inoperable patient. Conclusions: This updated ARS AUC summary provides guidelines for the multimodality treatment of resectable gastric adenocarcinoma.